Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O60936

UPID:
NOL3_HUMAN

ALTERNATIVE NAMES:
Apoptosis repressor with CARD; Muscle-enriched cytoplasmic protein; Nucleolar protein of 30 kDa

ALTERNATIVE UPACC:
O60936; B4DFL0; O60937

BACKGROUND:
The Nucleolar protein 3, with alternative names such as Muscle-enriched cytoplasmic protein, is pivotal in apoptosis suppression. It blocks multiple cell death modes by interacting with apoptosis-related proteins and inhibiting pathways like those triggered by TNF, hypoxia, and calcium-mediated stress, thus maintaining cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Nucleolar protein 3 could open doors to potential therapeutic strategies, especially considering its critical function in preventing familial myoclonus 1, highlighting its potential in neuroprotective treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.